Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

References

• SchaferAIThe hypercoagulable statesAnn Intern Med19851026814 8283158262
   PubMed Web of Science ®Google Scholar
• FradeLJGde la CalleHAlavaINavarroJLCreightonLJGaffineyPJDiabetes as a hypercoagulable state: its relationship with fibrin fragments and vascular damageThromb Res1987475533 5403118498
   PubMed Web of Science ®Google Scholar
• SeshasalSRKaptogeSThompsonADiabetes mellitus, fasting glucose, and risk of cause-specific deathN Engl J Med20113649829 84121366474
   PubMed Web of Science ®Google Scholar
• ScheenAJCardiovascular effects of gliptinsNat Rev Cardiol201310273 8423296071
   PubMed Web of Science ®Google Scholar
• CominaciniLPasiniAFGarbinUElevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic controlDiabetologia19953891122 11248591829
   PubMed Web of Science ®Google Scholar
• LimYCSnappKKansasGSCamphausenRDingHLuscinskasFWImportant contributions of P-selectin glycoprotein ligand-1-mediated secondary capture to human monocyte adhesion to P-selectin, E-selectin, and TNF-α-activated endothelium under flow in vitroJ Immunol199816152501 25089725249
   PubMed Web of Science ®Google Scholar
• NomuraSShouzuAOmotoSNishikawaMFukuharaSSignificance of chemokines and activated platelets in patients with diabetesClin Exp Immunol20001213437 44310971508
   PubMed Web of Science ®Google Scholar
• NakagamiTHyperglycaemia and mortality from all cause and from cardiovascular disease in five populations of Asian originDiabetologia2004473385 39414985967
   PubMed Web of Science ®Google Scholar
• OuchiNKiharaSAritaYAdiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathwayCirculation2000102111296 130110982546
   PubMed Web of Science ®Google Scholar
• AritaYKiharaSOuchiNParadoxical decrease of an adipose-specific protein, adiponectin, in obesityBiochem Biophys Res Com1999257179 8310092513
   PubMed Web of Science ®Google Scholar
• HottaKFunahashiTAritaYPlasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patientsArterioscler Thromb Vasc Biol20002061595 159910845877
   PubMed Web of Science ®Google Scholar
• WeyerCFunahashiTTanakaSHypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemiaJ Clin Endocrinol Metab20018651930 193511344187
   PubMed Web of Science ®Google Scholar
• ChenHMontagnaniMFunahashiTShimomuraIQuonMJAdiponectin stimulates production of nitric oxide in vascular endothelial cellsJ Biol Chem20032784545021 4502612944390
   PubMed Web of Science ®Google Scholar
• HattoriYSuzukiMHattoriSKasaiKGlobular adiponectin upregulates nitric oxide production in vascular endothelial cellsDiabetologia200346111543 154914551684
   PubMed Web of Science ®Google Scholar
• ZiemanSJMelenovskyVClattenburgLAdvanced glycation end product crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertensionJ Hypertens2007253577 58317278974
   PubMed Web of Science ®Google Scholar
• HofmannMADrurySFuCRAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptidesCell1999977889 90110399917
   PubMed Web of Science ®Google Scholar
• HaslbeckKMSchleicherEBierhausAThe AGE/RAGE/NF-kB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT)Exp Clin Endocrinol Diabetes20051135288 29115926115
   PubMed Web of Science ®Google Scholar
• BierhausANawrothPPMultiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in Kalousova M inflammation, immune responses and diabetes mellitus and its complicationsDiabetologia200952112251 226319636529
   PubMed Web of Science ®Google Scholar
• YanSFYanSDRamasamyRSchmidtAMTempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammationAnn Med2009416408 42219322705
   PubMed Web of Science ®Google Scholar
• KalousováMJáchymováMMestekOReceptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patientsNephrol Dial Transplant20072272020 202617347281
   PubMed Web of Science ®Google Scholar
• GrossinNWautierMPMeasTGuillausseauPJMassinPWautierJLSeverity of diabetic microvascular complications is associated with a low soluble RAGE levelDiabetes Metab2008344392 39518701333
   PubMed Web of Science ®Google Scholar
• HermanGAStevensCVan DyckKPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesClin Pharmacol Ther2005786675 68816338283
   PubMed Web of Science ®Google Scholar
• HermanGABergmanAStevensCEffect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetesJ Clin Endocrinol Metab200691114612 461916912128
   PubMed Web of Science ®Google Scholar
• HeransenKKipnesMLuoEEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab200795733 74517593236
   PubMed Web of Science ®Google Scholar
• IwamotoYTaniguchiTNonakaKDose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitusEndocr J2010575383 39420332588
   PubMed Web of Science ®Google Scholar
• KimSAShimWHLeeEHPredictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitusDiabetes Metab J2011353159 16521738898
   PubMedGoogle Scholar
• PolonskyKSGivenBDHirschLJAbnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitusN Engl J Med1988318191231 12393283554
   PubMed Web of Science ®Google Scholar
• WendtTTanjiNGuoJGlucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathyJ Am Soc Nephrol20031451383 139512707408
   PubMed Web of Science ®Google Scholar
• Soro-PaavonenAWatsonAMLiJReceptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetesDiabetes20085792461 246918511846
   PubMed Web of Science ®Google Scholar
• ThomasMCSöderlundJLehtoMSoluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetesDiabetologia201154102669 267721607631
   PubMed Web of Science ®Google Scholar
• KoyamaHShojiTYokoyamaHPlasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosisArterioscler Thromb Vasc Biol200525122587 259316224056
   PubMed Web of Science ®Google Scholar
• GohdaTTanimotoMMoonJYIncreased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal functionDiabetes Res Clin Pract2008812196 20118550199
   PubMed Web of Science ®Google Scholar
• SembaRDFerrucciLFinkJCAdvanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling womenAm J Kidney Dis200953151 5818789567
   PubMed Web of Science ®Google Scholar
• KatakamiNMatsuhisaMKanetoHYamasakiYSerum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patientsAtherosclerosis2007190122 2316876804
   PubMed Web of Science ®Google Scholar
• TamHLShiuSWWongYChowWSBetteridgeDJTanKCEffects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetesAtherosclerosis20102091173 17719733353
   PubMed Web of Science ®Google Scholar
• KurowskaEMNitric oxide therapies in vascular diseasesCurr Pharm Des200283155 16611812265
   PubMed Web of Science ®Google Scholar
• OuchiNKiharaSAritaYNovel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectinCirculation1999100252473 247610604883
   PubMed Web of Science ®Google Scholar
• MaedaHKubotaATanakaYTakeuchiYMatsubaIThe safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetesDiabetes Res Clin Pract2012951e20 e2222055835
   PubMed Web of Science ®Google Scholar
• HongESKhangARYoonJWComparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI studyDiabetes Obes Metab2012149795 80222443183
   PubMed Web of Science ®Google Scholar
• MoriHOkadaYAraoTTanakaYSitagliptin improves albuminuria in patients with type 2 diabetes mellitusJ Diabetes Invest201453313 319
   PubMed Web of Science ®Google Scholar
• ShimabukuroMHigaNAsahiTHypoadiponectinemia is closely linked to endothelial dysfunction in manJ Clin Endocr Metab20038873236 324012843170
   PubMed Web of Science ®Google Scholar
• NomuraSShouzuAOmotoSCorrelation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitusThromb Res2008122139 4517920663
   PubMed Web of Science ®Google Scholar
• GuptaAKVermaAKKailashiyaJSitagliptin: antiplatelet effect in diabetes and healthy volunteersPlatelets2012238565 57022950787
   PubMed Web of Science ®Google Scholar
• WangYLamKSChanLPost-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complexJ Biol Chem20062812416391 1640016621799
   PubMed Web of Science ®Google Scholar
• FülöpNMarchaseRBChathamJCRole of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular systemCardiovasc Res2007732288 29716970929
   PubMed Web of Science ®Google Scholar
• FülöpNMasonMMDuttaKImpact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heartAm J Physiol Cell Physiol20072924C1370 C137817135297
   PubMed Web of Science ®Google Scholar
• OchiaiHOokaHShidaCIshikawaTInoueDOkazakiRAcarbose treatment increases serum total adiponectin levels in patients with type 2 diabetesEndocr J2008553549 55618480556
   PubMed Web of Science ®Google Scholar
• KnopFKVilsbøllTLarsenSMadsbadSHolstJJKrarupTNo hypoglycemia after subcutaneous administration of glucagons-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisDiabetes Care20032692581 258712941722
   PubMed Web of Science ®Google Scholar
• IshibashiYMatsuiTTakeuchiMYamagishiSSitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cellsHorm Metab Res2011431731 73421932180
   PubMed Web of Science ®Google Scholar
• PocaiACarringtonPEAdamsJRGlucagon-like peptide 1/glucagons receptor dual agonism reverses obesity in miceDiabetes200958102258 226619602537
   PubMed Web of Science ®Google Scholar
• Kim Chung leTHosakaTYoshidaMExendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expressionBiochem Biophys Res Comm20093903613 61819850014
   PubMed Web of Science ®Google Scholar
• DhindsaSJialalIPotential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitusCurr Diabetes Rep2014142463
   PubMed Web of Science ®Google Scholar